Collectively, these results suggest that PAK4KO decreased the tumour weight, increased the vessel diameter and angiogenesis with higher fibronectin deposition, and reduced hypoxia, but did not affect the gemcitabine efficacy. The gene discussed is FN1; the disease is neoplasm.